Clarifique Pro-Solution Serum - Brightening & Dark Spot Reducing

Brightening serum that visibly reduces dark spots and post-acne marks and tightens the look of pores.

Formulated with 10% PHA (polyhydroxy acid), niacinamide, and beech bud extract, Clarifique Pro-Solution is a concentrated brightening treatment that delivers powerful results over time without being harsh on skin. Women see brighter skin in one week and visibly tighter pores in four weeks. In eight weeks, dark spots and post-acne mark skin discoloration are visibly reduced. From light to melanin-rich skin tones, 9 out of 10 women saw a visible transformation in their skin after using one bottle of Clarifique Pro-Solution* – including those with sensitive skin or acne-prone skin.

For those who struggle with concerns like uneven skin tone, dark spots, and skin discoloration, it can be difficult to find a brightening serum that is both effective and gentle. Concentrated brightening serums formulated with AHA or BHA may cause sensations like burning or tingling when applied – especially if you have sensitive skin. Powered by 10% PHA, Clarifique Pro-Solution strikes the perfect balance between results and comfort. PHA has a larger molecular structure compared to AHA or BHA, allowing it to gently exfoliate the surface of the skin to minimize irritation. When PHA is combined with an ingredient like niacinamide, it delivers visible brightening results without the unwanted harshness.
*Based on self-assessment results in a 10-week consumer study with 64 women

CONSUMER SELF-ASSESSMENT RESULTS*
• 96% agree skin texture looks refined
• 92% agree skin looks brighter
• 89% agree skin tone looks more even & pores look tightened
• 84% agree dark spots and skin discoloration are visibly reduced
*Based on self-assessment results in a 10-week consumer study with 64 women

CLINICALLY TESTED RESULTS*
• Post-acne marks are visibly reduced -29.7%
• Dark spots are visibly reduced -20.3%
• Pores are visibly reduced -18.7%
• Skin tone is more even +28.2%
*Based on a 10-week clinical study with 64 women